Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

More stories

Neoclassical federal agency building exterior at dawn, symbolizing a regulatory safety decision
Policy

Why the FDA Put a Vision-Loss Warning on Every GLP-1 Label

The agency combed trials, real-world claims data, and case reports for two years before putting NAION on every GLP-1 label. The absolute risk is tiny, the relative signal is real, and the decision says a lot about how FDA weighs incomplete evidence.

In depth

Bolt's Original Stockholders Own 6.9% After the Prana Reverse Merger

A sign-and-close reverse merger leaves Bolt's original stockholders with 6.9% of the company as Prana's IL-4Rα/TSLP bispecific inherits the Nasdaq listing, backed by a $120 million placement closing today.

Read the story

Pipeline

See all